Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELACS: Early vs Late Anticoagulation in CSDH
NCT06696079Phase 3Recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Countries
- 2
01
Overview
Phase 3, randomised, single-blind trial in Atrial fibrillation (AFib) (2 arms). Primary endpoint: Rate of composite outcome of vascular events at 90 days. Started Jul 2025; status: recruiting.
02
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06696079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06696079.